In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Atugen AG

Division of Silence Therapeutics PLC
www.silence-therapeutics.com

Latest From Atugen AG

In RNAi, Technology Proliferates Beyond the Big Two

If 2006 was a breakout year for RNAi the concept, then 2007 could be a breakout year for RNAi drug development itself. In the past few years there has been a surge of newcomers to the space, in some cases sporting high-quality venture backers and boldfaced names in RNAi. Some companies have decided to play ball with the industry leaders, sublicensing Alnylam's IP around their chosen targets, for example; others have filed their own IP-either outside the Alnylam and Merck umbrellas or putting them on a relatively slow-motion collision course with the two power brokers; still others have argued that patenting novel delivery technologies will provide them with the necessary edge in licensing negotiations, should they come about, or with pharmaceutical partners.
BioPharmaceutical Business Strategies

Trade Sales Trump IPOs, Even for Platforms

Europe's summertime flurry of private biotech sell-offs points to growing pragmatism among management and VCs, and still-poor valuations on the public markets. Firms which haven't already considered the trade sale opportunity should do so--even early-stage, pre-product platform groups.
BioPharmaceutical Strategy

Recent Dealmaking (04/2004)

Summarizing the month in European dealmaking.

Spirogen Ltd.

UK start-up Spirogen Ltd. is developing novel DNA-targeting drugs to treat cancer.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Metabolic Disorders
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Atugen Biotechnology GMBH
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Silence Therapeutics PLC
  • Senior Management
  • Peter Buckel, CEO
    Thomas Christély, CFO
    Zisi Fotev, PhD, VP, Bus. Dev.
    Klaus Giese, PhD, VP, Research
  • Contact Info
  • Atugen AG
    Phone: (49) 309 489 27 00
    Robert-Rössle-Strasse 10
    Berlin, 13125
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register